keyword
MENU ▼
Read by QxMD icon Read
search

HSCT

keyword
https://www.readbyqxmd.com/read/29449660/gut-microbiota-injury-in-allogeneic-haematopoietic-stem-cell-transplantation
#1
REVIEW
Yusuke Shono, Marcel R M van den Brink
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is considered to be the strongest curative immunotherapy for various malignancies (primarily, but not limited to, haematologic malignancies). However, application of allo-HSCT is limited owing to its life-threatening major complications, such as graft-versus-host disease (GVHD), relapse and infections. Recent advances in large-scale DNA sequencing technology have facilitated rapid identification of the microorganisms that make up the microbiota and evaluation of their interactions with host immunity in various diseases, including cancer...
February 16, 2018: Nature Reviews. Cancer
https://www.readbyqxmd.com/read/29448057/hla-matched-sibling-vs-unrelated-vs-haploidentical-related-donor-allogeneic-hematopoietic-stem-cell-transplantation-for-patients-aged-over-60-years-with-acute-myeloid-leukemia-a-single-center-donor-comparison
#2
Raynier Devillier, Faezeh Legrand, Jérôme Rey, Luca Castagna, Sabine Fürst, Angela Granata, Aude Charbonnier, Samia Harbi, Evelyne d'Incan, Thomas Pagliardini, Catherine Faucher, Claude Lemarie, Colombe Saillard, Boris Calmels, Bilal Mohty, Valerio Maisano, Pierre-Jean Weiller, Christian Chabannon, Norbert Vey, Didier Blaise
Haploidentical related donor (HRD) allogeneic hematopoietic stem cell transplantation (Allo-HSCT) was developed as a valid option for the treatment of acute myeloid leukemia (AML) in the absence of a matched donor. However, many investigators are reluctant to consider the use of this alternative in elderly patients, anticipating high morbidity. Here, we report a single-center comparison of HRD vs. matched sibling donor (MSD) and unrelated donor (UD) Allo-HSCT for patients with AML aged ≥60 years. Ninety-four patients (MSD: n = 31; UD: n = 30; HRD: n = 33) were analyzed...
February 12, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29444931/complete-remission-with-reduction-of-high-risk-clones-following-haploidentical-nk-cell-therapy-against-mds-and-aml
#3
Andreas T Björklund, Mattias Carlsten, Ebba Sohlberg, Lisa L Liu, Trevor Clancy, Mohsen Karimi, Sarah Cooley, Jeffrey S Miller, Monika Klimkowska, Marie Schaffer, Emma Watz, Kristina I Wikstrom, Pontus Blomberg, Bjorn E Wahlin, Marzia Palma, Lotta Hansson, Per Ljungman, Eva Hellström-Lindberg, Hans-Gustaf Ljunggren, Karl-Johan Malmberg
PURPOSE: To evaluate the safety, efficacy and immunobiological correlates of allogeneic NK cell-based therapy in primary chemotherapy-refractory or relapsed high-risk myelodysplastic syndrome (MDS), secondary AML (MDS/AML), and de novo AML patients. EXPERIMENTAL DESIGN: Sixteen patients received fludarabine/cyclophosphamide conditioning combined with total lymphoid irradiation followed by adoptive immunotherapy with IL-2-activated haploidentical NK cells. RESULTS: NK cell infusions were well tolerated with only transient adverse events observed in the 16 patients...
February 14, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29442161/allogeneic-hematopoietic-stem-cell-transplantation-in-primary-cutaneous-t-cell-lymphoma
#4
Laura Cudillo, Raffaella Cerretti, Alessandra Picardi, Benedetta Mariotti, Gottardo De Angelis, Maria Cantonetti, Massimiliano Postorino, Eleonora Ceresoli, Giovanna De Santis, Daniela Nasso, Francesco Pisani, Enrico Scala, Fabio Di Piazza, Alessandro Lanti
In our retrospective study, 16 patients affected by advanced cutaneous T cell lymphoma (CTCL) underwent allogeneic hematopoietic stem cell transplantation (HSCT). Two patients (12.5%) were in complete remission (CR), nine (56.3%) in partial remission (PR), and five (31.2%) with active disease. The patients were transplanted from an HLA-identical (n = 7) from a mismatched (n = 1) or haploidentical (n = 1) sibling, from matched unrelated donor (n = 5), or from a single cord blood unit (n = 2). Conditioning regimen was standard myeloablative in 6 patients and at reduced intensity in 10...
February 13, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29440738/advantages-of-non-cryopreserved-autologous-hematopoietic-stem-cell-transplantation-against-a-cryopreserved-strategy
#5
M Sarmiento, P Ramírez, R Parody, M Q Salas, N Beffermann, V Jara, P Bertín, I Pizarro, C Lorca, E Rivera, M Galleguillos, M Ocqueteau, I Sánchez-Ortega, B Patiño, A Sureda
Autologous stem cell transplantation (auto-HSCT) is an effective treatment strategy for hematological malignancies. The standard mode of handling hematopoietic progenitors for the autologous procedure (CRYO) consists on its collection and freezing with dimethyl sulfoxide (DMSO) and its subsequent thawing and re-infusion. This process is toxic and expensive. Non-cryopreserved (non-CRYO) is a less expensive mode of auto-HSCT. We designed a comparative study between both strategies performed in two different centers to analyze the short-term complications...
February 13, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29439920/stem-cell-mobilization-kinetics-in-elderly-patients-with-multiple-myeloma
#6
Mehmet Hilmi Dogu, Hikmetullah Batgi, Mehmet Ali Erkurt, Sibel Hacioglu, Emre Tekgunduz, Emin Kaya, Dicle Iskender, Rafet Eren, Irfan Kuku, Fevzi Altuntas
In this study, we aimed to investigate whether the procedure and product kinetics differ according to age groups in advanced-age MM patients who underwent autologous HSCT. 59 patients who underwent autologous HSCT were retrospectively analyzed. Then, the patients were divided into two groups as 60-65 years and ≥65 years. It was significantly lower in ≥65 years group (p = 0.008) and proportionally, the procedure duration was also significantly shortened in this group (p = 0.013). Total number of collected CD34 positive stem cells was 6...
February 1, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29438096/fda-approval-summary-lenalidomide-as-maintenance-therapy-after-autologous-stem-cell-transplant-in-newly-diagnosed-multiple-myeloma
#7
Elizabeth Dianne Pulte, Andrew Dmytrijuk, Lei Nie, Kirsten B Goldberg, Amy E McKee, Ann T Farrell, Richard Pazdur
On February 22, 2017, the U.S. Food and Drug Administration (FDA) granted approval for the use of lenalidomide as maintenance therapy after autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with multiple myeloma. The approval was based on evidence from two randomized, blinded trials of maintenance lenalidomide versus placebo in patients with myeloma who had undergone auto-HSCT along with a third trial of lenalidomide versus no therapy. Each of the trials demonstrated superior progression-free survival for the patients treated with lenalidomide...
February 7, 2018: Oncologist
https://www.readbyqxmd.com/read/29433372/characterization-of-innate-immune-viral-sensors-in-patients-following-allogeneic-hematopoietic-stem-cell-transplantation
#8
Sarah L Caddy, Meng Wang, Pramila Krishnamurthy, Benjamin Uttenthal, Anita Chandra, Charles Crawley, Leo C James
Viral infection is a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplant (HSCT), with up to one in four deaths directly linked to viral disease. Whilst awaiting lymphocyte reconstitution post-HSCT, the innate antiviral immune response is the first line of defense against invading viruses. Several novel innate viral-sensing pathways have recently been characterized, but their physiological importance in humans is poorly understood. We analyzed a panel of innate viral-sensor genes in HSCT patients, and assessed whether differences in innate antiviral responses could account for variation in susceptibility to viral infections...
January 1, 2018: Innate Immunity
https://www.readbyqxmd.com/read/29432583/the-clinical-utility-of-pgd-with-hla-matching-a-collaborative-multi-centre-eshre-study
#9
G Kakourou, S Kahraman, G C Ekmekci, H A Tac, G Kourlaba, E Kourkouni, A Cervero Sanz, J Martin, H Malmgren, C Giménez, V Gold, F Carvalho, C Billi, J F C Chow, X Vendrell, G Kokkali, J Liss, J Steffann, J Traeger-Synodinos
STUDY QUESTION: Has PGD-HLA been successful relative to diagnostic and clinical efficacy? SUMMARY ANSWER: The diagnostic efficacy of PGD-HLA protocols was found lower in this study in comparison to published PGD-HLA protocols and to that reported for general PGD by ESHRE (78.5 vs 94.1% and vs 92.6%, respectively), while the clinical efficacy has proven very difficult to assess due to inadequate follow-up of both the ART/PGD and HSCT procedure outcomes. WHAT IS KNOWN ALREADY: The first clinical cases for PGD-HLA were reported in 2001...
February 8, 2018: Human Reproduction
https://www.readbyqxmd.com/read/29431621/haploidentical-hsct-for-hemoglobinopathies-improved-outcomes-with-tcr%C3%AE-%C3%AE-cd19-depleted-grafts
#10
Javid Gaziev, Antonella Isgrò, Pietro Sodani, Katia Paciaroni, Gioia De Angelis, Marco Marziali, Michela Ribersani, Cecilia Alfieri, Alessandro Lanti, Tiziana Galluccio, Gaspare Adorno, Marco Andreani
We examined outcomes of haploidentical hematopoietic cell transplantation (haplo-HCT) using T-cell receptor αβ + (TCRαβ + )/CD19 + -depleted grafts (TCR group, 14 patients) in children with hemoglobinopathies. Patients received a preparative regimen consisting of busulfan, thiotepa, cyclophosphamide, and antithymocyte globulin preceded by fludarabine, hydroxyurea, and azathioprine. The median follow-up among surviving patients was 3.9 years. The 5-year probabilities of overall survival (OS) and disease-free survival (DFS) were 84% and 69%, respectively...
February 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/29426831/cardiovascular-risk-factors-and-subclinical-organ-damage-after-hematopoietic-stem-cell-transplantation-in-pediatric-age
#11
Bianca Borchert-Mörlins, Nima Memaran, Martin Sauer, Britta Maecker-Kolhoff, Karl-Walter Sykora, Ricarda Blöte, Elena Bauer, Bernhard M W Schmidt, Anette Melk, Rita Beier
Advances in allogeneic hematopoietic stem cell transplantation (HSCT) in malignant and non-malignant diseases result in more long-term survivors, in whom cardiovascular (CV) disease is one leading non-cancer cause of death. This study aimed to evaluate risk factors and subclinical CV organ damage in survivors after HSCT in pediatric age. We enrolled 64 children in a cross-sectional approach 3.3 ± 3.1 years after HSCT. Anthropometric data, laboratory values, office and 24-h ambulatory blood pressure monitoring (ABPM) were evaluated, showing a high prevalence of obesity, hypertension and dyslipidemia...
February 9, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29425515/reprint-of-virus-specific-t-cells-broadening-applicability
#12
REVIEW
A John Barrett, Susan Prockop, Catherine M Bollard
Virus infection remains an appreciable cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). Although pharmacotherapy and/or antibody therapy may help prevent or treat viral disease, these drugs are expensive, toxic, and often ineffective due to primary or secondary resistance. Further, effective treatments are limited for many infections (eg, adenovirus, BK virus), which are increasingly detected after alternative donor transplants. These deficiencies in conventional therapeutics have increased interest in an immunotherapeutic approach to viral disorders, leading to adoptive transfer of virus-specific cytotoxic T lymphocytes (VSTs), which can rapidly reconstitute antiviral immunity post-transplantation without causing graft-versus-host disease...
March 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29424696/upper-respiratory-viral-infections-in-patients-with-haematological-malignancies-after-allogeneic-haematopoietic-stem-cell-transplantation-a-retrospective-study
#13
Erden Atilla, Didem Sahin, Pinar Ataca Atilla, Istar Dolapci, Alper Tekeli, Sinem Civriz Bozdag, Meltem Kurt Yuksel, Selami Kocak Toprak, Osman Ilhan, Onder Arslan, Muhit Ozcan, Gunhan Gurman, Pervin Topcuoglu
BACKGROUND: Community respiratory viruses (CRVs) are associated with upper respiratory viral infections (URI), pneumonia or life-threatening respiratory disease in patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our aim is to demonstrate our URI experience related to CRVs after allo-HSCT. METHODS: From January 2013 to November 2015, 39 post allo-HSCT patients with acute URI symptoms were included to the study. We evaluated CRVs by multiplex PCR from nasopharyngeal wash and throat swabs...
February 9, 2018: Antiviral Therapy
https://www.readbyqxmd.com/read/29424670/the-impact-of-posttraumatic-stress-symptoms-on-social-support-and-social-conflict-during-hematopoietic-stem-cell-transplant
#14
James I Gerhart, Yasmin Asvat, Teresa A Lillis, Henry Fung, Johanna Grosse, Stevan E Hobfoll
PURPOSE/OBJECTIVES: Social support and its relationship to psychological distress are of interest in hematopoietic stem cell transplant (HSCT) as patients are dependent on caregivers pre-, during, and posttransplant. Although social support is critical for managing stress and trauma, posttraumatic stress symptoms (PTSS) may erode social support and evoke conflict and abandonment within the support system. This study aimed to evaluate whether PTSS were associated with lower support and social conflict in a sample of patients undergoing HSCT...
February 9, 2018: Journal of Psychosocial Oncology
https://www.readbyqxmd.com/read/29423758/impact-of-pre-transplantation-minimal-residual-disease-determined-by-multiparameter-flow-cytometry-on-the-outcome-of-aml-patients-with-flt3-itd-after-allogeneic-stem-cell-transplantation
#15
Xiaosu Zhao, Zhidong Wang, Guorui Ruan, Yanrong Liu, Yu Wang, Xiaohui Zhang, Lanping Xu, Xiaojun Huang, Yingjun Chang
In this study, using multiparameter flow cytometry (FCM), we investigate the impact of minimal residual disease prior to transplantation (pre-MRD) on the transplant outcomes of AML patients with fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutation. A total of 20 patients who received HLA-matched sibling donor transplantation (MSDT) and 63 patients who received unmanipulated haploidentical hematopoietic stem cell transplantation (haplo-HSCT) were enrolled. Patients were classified into four groups based on the status of pre-FCM: group 1 with positive pre-FCM before MSDT, group 2 with negative pre-FCM before MSDT, group 3 with positive pre-FCM before haplo-HSCT, and group 4 with positive pre-FCM before haplo-HSCT...
February 8, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29423036/salvaged-allogeneic-hematopoietic-stem-cell-transplantation-for-pediatric-chemotherapy-refractory-acute-leukemia
#16
Jingbo Wang, Lei Yuan, Haoyu Cheng, Xinhong Fei, Yumin Yin, Jiangying Gu, Song Xue, Junbao He, Fan Yang, Xiaocan Wang, Yixin Yang, Weijie Zhang
There is an ongoing debate concerning the performance of salvaged allogeneic hematopoietic stem cell transplantation (allo-HSCT) in pediatric patients with acute refractory leukemia, in whom the prognosis is quite dismal. Few studies have ever been conducted on this subject. This may be partly due to missed opportunities by majority of the patients in such situations. To investigate the feasibility, evaluate the efficiency, and identify the prognostic factors of allo-HSCT in this sub-setting, the authors performed a single institution-based retrospective analysis...
January 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29417695/visual-perceptual-skills-and-visual-motor-integration-in-children-and-adolescents-after-allogeneic-hematopoietic-stem-cell-transplantation
#17
Kristina Teär Fahnehjelm, Alba Lucia Törnquist, Monica Olsson, Jacek Winiarski, Ulla Ek
The aim of the study was to study visual acuity, visual perceptual, and VMI skills in patients after HSCT in childhood. Tests of visual perceptual skills, VMI, and visual acuity were performed in 102 children/adolescents (age range 4.3-20.9 years). Mean time from HSCT to testing was 6.0 years (0.9-17.5 years). Visual acuity was median 1.0 decimal (range 0.16-1.6). Visual perceptual skills (memory, form constancy, visual sequential memory) and VMI were low compared to age-equivalent normative data with, respectively, 36%, 45%, 60%, and 46% of all patients performing below the 25 percentile...
February 8, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29417689/efficacy-of-high-dose-steroids-for-bronchiolitis-obliterans-syndrome-post-pediatric-hematopoietic-stem-cell-transplantation
#18
Ehud Even-Or, Hasan Ghandourah, Muhammad Ali, Joerg Krueger, Neil B Sweezey, Tal Schechter
BOS is the pulmonary manifestation of cGvHD post-allogeneic HSCT. Survival and treatment of this often fatal complication have not improved over the last 20 years and there is no clear standard of care. For the past 10 years, BOS was treated in our center with monthly cycles of HDPS. We reviewed the outcomes of patients with post-HSCT BOS who met the diagnostic criteria for BOS as per the NIH consensus and were treated with at least one cycle of methylprednisolone at a dose of 10-30 mg/kg/d×3 d. We collected demographic and clinical data, responses to treatment and results of pulmonary function tests at several time points...
February 7, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29417201/cd19-targeted-car-t-therapy-versus-chemotherapy-in-re-induction-treatment-of-refractory-relapsed-acute-lymphoblastic-leukemia-results-of-a-case-controlled-study
#19
Guoqing Wei, Yongxian Hu, Chengfei Pu, Jian Yu, Yi Luo, Jimin Shi, Qu Cui, Wenjun Wu, Jinping Wang, Lei Xiao, Zhao Wu, He Huang
Chimeric antigen receptor modified T cells against CD19 (CART19s) have potent anti-leukemia activities in patients with refractory/relapsed acute lymphoblastic leukemia (R/R ALL). This study was designed to investigate the correlation between safety/efficacy and therapeutic modalities including chemotherapy and CART19 therapy. Total 23 and 69 patients were enrolled in the CART19 group and in the chemotherapy group, respectively. The safety and efficacy profiles of 66 and 22 patients in the 2 groups were evaluated...
February 7, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29416633/allogeneic-hematopoietic-stem-cell-transplantation-for-relapsed-acute-myeloid-leukemia-in-eto-positive-with-reduced-intensity-conditioning
#20
Zhi Guo, Chen Xu, Hu Chen
Objective: This research is conducted under the intention of exploring the efficacy and safety of reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of relapsed ETO positive acute myeloid leukemia (AML). Materials and Methods: Treatment of 15 cases referring to recurrent ETO positive acute myeloid leukemia in an army hospital from January 2010 to January 2013 through allo-HSCT with reduced-intensity conditioning...
January 2, 2018: Oncotarget
keyword
keyword
18503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"